Translational research of photodynamic therapy with acridine orange which targets cancer acidity

Current Pharmaceutical Design

Volumn 18, Issue 10, 2012, Pages 1414-1420

  Kusuzaki, Katsuyuki ^a,b,g   Hosogi, Shigekuni ^b   Ashihara, Eishi ^b   Matsubara, Takao ^c   Satonaka, Haruhiko ^c   Nakamura, Tomoki ^c   Matsumine, Akihiko ^c   Sudo, Akihiro ^c   Uchida, Atsumasa ^c   Murata, Hiroaki ^d   Baldini, Nicola ^e   Fais, Stefano ^f   Marunaka, Yoshinori ^b,g  

^a Kyoto Kujo Hospital   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^g Takatsuki city   (Japan)

Author keywords

Acridine orange; Cancer acidity; Lysosome; Photodynamic therapy; Proton

Indexed keywords

ACRIDINE ORANGE; LYSOSOME ENZYME; METHYLENE BLUE; OXYGEN DERIVATIVE; PROTON; PROTON PUMP;

ACIDITY; APOPTOSIS; ARTICLE; BLUE LIGHT; CANCER ACIDITY; CANCER CELL; CANCER RADIOTHERAPY; CANCER STAGING; CELL PROLIFERATION; CONFOCAL LASER MICROSCOPY; CYTOREDUCTIVE SURGERY; DRUG CARCINOGENICITY; EXTRACELLULAR FLUID; FATTY ACID OXIDATION; GLYCOLYSIS; HUMAN; HYPOXIA; LIMB SALVAGE; LYSOSOME; LYSOSOME MEMBRANE; METHEMOGLOBINEMIA; MUSCULOSKELETAL SARCOMA; MYOSARCOMA; NONHUMAN; OSTEOSARCOMA; PHOTODYNAMIC THERAPY; PHOTON; PHOTON THERAPY; PRIORITY JOURNAL; RADIODYNAMIC THERAPY; TRANSLATIONAL RESEARCH; WIDE EXCISION; X IRRADIATION;

EID: 84863248377     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799504812     Document Type: Article

References (59)

1. Kusuzaki K, Minami G, Takeshita H, et al. Photodynamic inactiva- tion with acridine orange on a multidrug-resistant mouse osteosar- coma cell line. Jpn J Cancer Res 2000; 91: 439-445.
2. Kusuzaki K, Aomori, K, Suginoshita, Minami G, et al. Total tumor cell elimination with minimum damage to normal tissues in muscu-loskeletal sarcomas by photodynamic reaction with acridine orange. Oncology 2000; 59: 174-180.
3. Kusuzaki K, Suginoshita T, Minami G, et al. Fluorovisualization effect of acridine orange on mouse osteosarcoma. Anticancer Res 2000; 20: 3019-324.
4. Hashiguchi S, Kusuzaki K, Murata H, et al. Acridine orange ex- cited by low-dose radiation has a strong cytocidal effect on mouse osteosarcoma. Oncology 2002; 62: 85-93.
5. [Kusuzaki K, Murata H, Matsubara T, et al. Clinical outcome of a new photodynamic therapy with acridine orange for synovial sarcomas. Photochem Photobiol 2005; 81: 705-709,
6. Kusuzaki K, Murata H, Matsubara T, et al.Clinical trial of pho- todynamic therapy using acridine orange with/without low dose radiation as new limb salvage modality in musculoskeletal sarcomas. Anticancer Res 2005; 25: 1225-1236.
7. Nakamura T, Kusuzaki K, Matsubara T, Matsumine A, Murata H, Uchida A. A new limb salvage surgery in cases of high-grade soft tissue sarcoma using photodynamic surgery, followed by photo-and radiodynamic therapy with acridine orange. J Surg Oncol 2008; 97: 523-528.
8. Matsubara T, Kusuzaki K, Matsumine A, et al. A new therapeutic modality involving acridine orange excitation by photon energy used during reduction surgery for rhabdomyosarcomas. Oncol Rep 2009; 21: 89-94.
9. Matsubara T, Kusuzaki K, Matsumine A, et al. Clinical outcomes of minimally invasive surgery using acridine orange for muscu-loskeletal sarcomas around the forearm, compared with conventional limb salvage surgery after wide resection. J Surg Oncol 2010; 102: 271-275.
10. Matsubara T, Kusuzaki K, Matsumine A, et al. Photodynamic therapy with acridine orange in musculoskeletal sarcomas. J Bone Joint Surg (Br) 2010; 92: 760-2.
11. [] Lewis RM and Goland PP. In vivo staining and retardation of tu mors in mice by acridine compounds. Am J Med Sci 1948; 215: 282-289.
12. Korgaonkar K and Sukhatankara J. Anti-tumor activity of the fluorescent dye, acridine orange, on Yoshida sarcoma (ascites). Br J Cancer 1963; 17: 471-473.
13. Tomson, SH, Emmett, EA, Fox SH. Photodestruction of mouse epithelial tumors after oral acridine orange and argon laser. Cancer Res 1974; 34: 3124-3127.
14. Tatsuta M, Yamamura H, Yamamoto R, et al. Destruction of implanted gastric tumors in rats by acridine orange photoactivation with an argon laser. Eur J Cancer Clin Oncol 1984; 20: 543-552.
15. Prosser E, Cox D, O'Kennedy R, Carroll K, van der Putten W. Effects of coumarins, haematoporphyrins and acridine orange on the viability and growth of Landshutz ascites tumour cells, in the presence and absence of photoradiation. Cancer Lett 1990; 52:71-77.
16. Ishikawa S, Nemoto R, Kanoh S, Kobayashi K, Ishizaka S. Pho-todynamic inactivation of bladder cancer cells (MGH-U1) sensitized with acridine orange and irradiated by argon laser. Tohoku J Exp Med 1984; 144: 265-271.
17. Zdolsek JM. Acridine orange-mediated photodamage to cultured cells. Apmis 1993; 101:127-132.
18. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glyco-lysis? Nature Review 2004; 4: 891-890.
19. Yamagata M, Hasuda K, Stamato T, Tannock IF. The contribution of lactic acid to acidification of tumors: studies of variant cells lacking lactate dehydrogenase. Br J Cancer 1998; 77: 1726-1731.
20. De Milito A, Canese R, Marino ML, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010 127: 207-219.
21. +-ATPase as a new strategy against cancer. Cancer Res 2007; 67: 10627-10630.
22. Acheson RM., Acridines 1973 Interscience Publishers John Wiley & Sons New York, London, Sydney, Tront.
23. Raab O. On the effect of fluorescent substances on infusoria. Z Biol 1900; 39: 524-526
24. Zdolsek JM, Olsson GM and Brunk UT. Photooxidative damage to lysosomes of cultured macrophages by acridine orange. Photochem Photobiol 1990; 51: 67-76.
25. Iwamoto Y, Itoyama T, Yasuda K, Morita et al. Photodynamic DNA strand breaking activities of acridine compounds. Biol Pharm Bull 1993; 16: 1244-1247.
26. Uggla, AH. The induction of chromosomal aberrations and SCEs by visible light in combination with dyes. II. Cell cycle dependence, and the effect of hydroxyl radical scavengers during light exposure in cultures of Chinese hamster ovary cells sensitized with acridine orange, Mutat Res 1990; 231: 233-242.
27. Cools AA, Jansen LHM. Fluorescence response of acridine orange to changes in pH gradients across liposome membranes. Experi-mentia 1986; 42: 954-956
28. Ibrahim ME, Pedersen H. Acridine orange fluorescence as male fertility test. Arch Andrology 1988; 20: 125-129
29. Zampieri A and Greenberg J. Mutagenesis by acridine orange and proflavin in Escherichia coli strain S. Mutat Res 1965; 2: 552-526.
30. McCann J, Choi E, Yamasaki E, Ames BN. Detection of carcino-genesis as mutagens in the Salmonella/microsome test: Assay of 300 chemicals. Proc Natl Acad Sci USA 1975; 72: 5135-5139.
31. Sastry KS, Gordon MP. The photodynamic inactivation of tobacco mosaic virus and its ribonucleic acid by acridine orange. Biochim Biophys Acta 1966; 129: 32-41.
32. Chessin, M. Photodynamic inactivation of infectious nucleic acid. Science 1960;132: 1840-1841.
33. Giorgio A, Rambaldi M, Maccario P, Ambrosone L, Moles DA. Detection of microorganisms in clinical specimens using slides prestained with acridine orange (AOS). Microbiologica 1989; 12: 97-100.
34. Rickman L, Long G, Oberst R, Cabanban A, Sangalang R, Smith J, Chulay J, Hoffman S. Rapid diagnosis of malaria by acridine orange staining of centrifuged parasites. Lancet 1989; 14: 68-71.
35. Barder G, Stiller D, Ruffert K. Fluorochrome stains for histological diagnosis of visceral mycoses. Nature 1965; 208: 796-797.
36. Kapuscinski J, Darzynkiewicz Z, Melamed MR. Interactions of acridine orange with nucleic acids. Properties of complexes of acridine orange with single stranded ribonucleic acid. Biochem Pharmacol 1983; 32: 3679-3694.
37. Amagasa J. Mechanisms of photodynamic inactivation of acridine orange-sensitized transfer RNA: participation of singlet oxygen and base damage leading to inactivation. J Radiat Res (Tokyo) 1986; 27: 339-351.
38. Zelenin AV. Fluorescence microscopy of lysosomes and related structures in living cells. Nature 1966; 212: 425-426.
39. Kusuzaki K, Murata H, Takeshita H, et al. Intracellular binding sites of acridine orange in living osteosarcoma cells. Anticancer Res 2000; 20:971-6.
40. Van Duuren, Sivak A, Katz C, Melchionne S. Tumorigenecity of acridine orange. Br J Cancer 1969; 23: 587-590.
41. Beeken WL, Roessner KD. In vivo labeling of hepatic lysosomes by intragastric administration of acridine orange. Lab Invest 1972; 26: 173-177
42. International Agency for Research on Cancer. Acridine Orange. In: IARC Monographs Program on the Evaluation of Carcinogenic Risks to Human. IARC Press Lyon, 1978;16:145
43. Kato A. Gastrofiberscopic diagnosis with acridine orange fluorescence. Gastroenterol Endosc 1970; 12: 351-362.
44. Coli A, et al: Myxoid monophasic synovial sarcoma: case report of an unusual histological variant. J Exp Clin Cancer Res 2006; 25: 287-291.
45. Tanbakuchi AA, Rouse AR, Udovich JA, Hatch KD, Gmitro AF. In vivo imaging of ovarian tissue using a novel confocal micro-laparoscope. J Biomed Optics 2009; 14: 044030.
46. Udovich JA, Besselsen DG, Gmitro AF. Assessment of acridine orange and SYTO 16 for in vivo imaging of the peritoneal tissues in mice. J Microscopy 2009; 234: 124-129.
47. Matsubara T, Kusuzaki K, Matsumine A, Shintani K, Satonaka H, Uchida A. Acridine orange used for photodynamic therapy accumulates in malignant musculoskeletal tumors depending on pH gradient. Anticancer Res 2006; 26: 187-194.
48. Clifton J., Leikin JB. Methylene blue. Am J Ther 2003; 10: 289-291.
49. Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci 2008; 39: 75-82.
50. Matsubara T, Kusuzaki K, Matsumine A, et al. Methylene blue in place of acridine as a photosensitizer in photodynamic therapy of osteosarcoma. In vivo 2008; 22: 297-303.
51. Satonaka H, Kusuzaki K, Shintani K, et al. Extracorporeal pho-todynamic image detection of mouse osteosarcoma in soft tissues utilizing fluorovisualization effect of acridine orange. Oncology 2007; 70:465-473.
52. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhyrase 9. Cancer Metastasis Rev 2007; 26: 299-310.
53. Moussavi-Harami F, Mollano A, Martin JA, Ayoob A, Domann FE, Gitelis S, Buckwalter JA. Intrinsic radiation resistance in human chondrosarcoma. BBRC 2006; 346: 379-385.
54. Hiruma H, Katakura T, Igawa S, Kanoh M, Fujimura T, Kawakami T. Vesicle disruption, plasma membrane bleb formation, and acute cell death caused by illumination with blue light in acridine orange-loaded malignant melanoma cells. J Photochem Photobiol B 2007; 86: 1-8.
55. Ueda H, Murata H, Takeshita H, Minami G, Hashiguchi S, Kubo T. Unifiltered xenon light is useful for photodynamic therapy with acridine orange. Anticancer Res 2005; 25: 3979-3984.
56. [Kusuzaki K, Hosogi S, Ashihara E, et al. New concept of limb salvage surgery in musculoskeletal sarcomas with acridine orange therapy. In Sarcoma: Symptoms, Causes and Treatment. 2012 (in press) Editor Butler EJ Nova Science Publishers, New York.
57. Vrouenreats MB, Visser GWM, Snow GB, van Dongen GAMS. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res 2003; 23:505-522.
58. Senge MO, Brandt JC. Temoporfin (Foascan, 5,10,15,20-tetra(m-hydroxyphenyl)chlorin)- A second-generation photosensitizer. Pho-tochem Photobiol 2011; 87:1240-1296
59. Robey IF, Baggett BK, Kirkpatrick ND, et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 2009; 69: 2260-2268.